Trial Profile

A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia [EXTENSION OF 700239254]

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ferumoxytol (Primary)
Indications Iron deficiency anaemia
Focus Therapeutic Use
Sponsors AMAG Pharmaceuticals

Most Recent Events

04 Dec 2018 Results assessing the efficacy of ferumoxytol in anemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
03 Dec 2018 According to AMAG Pharmaceuticals Media Release, data from this study were Presented at the American Society of Hematology Annual Meeting.
03 Dec 2018 Results published in the AMAG Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com